Načítá se...
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
BACKGROUND: First-line treatments for nonsmall cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations have been evaluated in various clinical trials. However, it remains unclear which is the optimal treatment. METHODS: A Bayesian network meta-analysis was used to assess...
Uloženo v:
| Vydáno v: | Ther Adv Med Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6937538/ https://ncbi.nlm.nih.gov/pubmed/31908655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835919891652 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|